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Oxidative stress and motorneuron disease 
Transgenic mice carrying mutated Cu/Zn superoxide dismutase genes 
provide insights into the pathogenesis of human motorneuron diseases and 
may be useful as models in the development and testing of therapies. 
Amyotrophic lateral sclerosis (ALS) is a lethal degenerative 
disorder of motorneurons. Recently, the disease has been 
shown to be linked to mutations in a gene on chromo-
some 21 encoding Cu/Zn-dependent superoxide dis-
mutase (SOD I); this linkage applies only to a small 
proportion of those ALS patients who have autosomal 
dominant inherited (familial) ALS [1] . The importance 
of this observation is two-fold: it provides an opportu-
nity for comparing therapeutic approaches between this 
group of patients and the large majority of ALS patients 
for whom the disease is not inherited, and it also pro-
vides scope for the production of animal models of ALS 
on a rational basis. 
SOD I has already been a focus of interest in studies of 
the neurodegenerative changes associated with Down's 
syndrome (trisomy 21), which resemble those occurring 
in Alzheimer's disease. Patients carrying only partial 
duplications of portions of chromosome 21 translocated 
to other chromosomes were analyzed in the search for 
the gene(s) responsible for the degenerative changes 
observed in Down's syndrome, and the 21q22 region was 
found to play a critical role [2]. Of the 100 or so genes 
within this region of chromosome 21, the SOD I gene 
was considered to be a good candidate for the gene 
affected in Down's syndrome: its duplication and conse-
quent over-expression could be responsible for the 
degenerative changes observed. Indeed, over-expression 
of SOD I in PC12 phaeochromocytoma cells results in 
impaired uptake of the neurotransmitters catecholamine 
and serotonin [3]. In order to obtain more detailed infor-
mation on the possible role of increased SOD I activity 
in neurodegenerative processes, transgenic mice were 
produced that over-express the human SOD I gene tran-
scribed from its own promoter [4,5]. Surprisingly, over-
expression of human SOD I in such mice [4] led to 
pathological changes in their motorneurons, such as the 
withdrawal and destruction of terminal axons at neuro-
muscular endplates and the development of multiple 
terminals smaller than those of wild-type age-matched 
mice [6] . 
The toxicity of excess SOD I activity in transgenic mice 
might be explained by the formation of hydroxyl (HO') 
radicals from hydrogen peroxide (H)O?), the production 
of which from superoxide (02'-) is- catalyzed by SOD I (Fig. 1). Whereas the superoxide radical itself is relatively 
unreactive [7], the hydroxyl radical can react with a great 
variety of molecules, in particular with the polyunsatu-
rated fatty acids found in cell membranes. This reaction 
generates lipid peroxyl radicals, which themselves react 
with neighbouring membrane fatty acids, leading to a 
chain reaction that finally destroys membrane integrity. 
Recently, convincing evidence was presented by Schubert 
and co-workers [8] that the toxicity of the Alzheimer's-
associated 13 amyloid protein for neuronal cells results 
from increased production of hydrogen peroxide and 
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Fig. 1. Two possible neurotoxic pathways, involving SOD I, which cou ld be responsible for motorneuron degeneration in familial ALS. 
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catalase, which catalyzes the conversion of hydrogen 
peroxide to water and oxygen, blocks the toxicity of 13 
amyloid, providing further evidence that hydrogen per-
oxide mediates amyloid's toxicity in neuronal cells. These 
data clearly indicate that hydrogen peroxide and its deriv-
atives such as hydroxyl radicals, can caese the lipid 
peroxidation that leads to neuronal cell death (Fig. 1). 
On the basis of these findings, it seems puzzling that loss 
of SOD I enzyme activity has been proposed to cause 
motorneuron degeneration, given that an increase in the 
same enzyme's activity causes cell damage. Several point 
mutations h ave been identified within the coding 
sequence of the SOD I gene in patients with familial 
ALS [1,9-11], located in exons 1, 2, 4 and 5, but not in 
exon 3, which encodes most of the loop around the 
metal ions that forms the active site of the enzyme 
[12,13] (Fig. 2). Measurements of SOD I enzyme activ-
ity showed a reduction of about 50 % in most fanlilial 
ALS patients [9 ,10,14], as expected for an autosomally 
inherited inactivating mutation that leaves one allele of 
the SOD I gene intact, but the way in which the muta-
tion reduces enzyme activity remains unresolved. It has 
been suggested that decreased enzyme activity results 
from either an allosteric effect on the active center of 
the enzyme or interference with the formation of 
enzyme dimers [9] . 
Can reduced SOD I activity lead to cell damage? This 
question, which could be addressed by generating SOD I 
gene 'knockout' mice, has unfortunately not yet been 
conclusively answered. With SOD I knockout mice, it 
would be possible to address the question of whether 
other SOD enzymes, such as the extracellular SOD III 
or mitochondrial SOD 11, can compensate for the lack of 
SOD I activity. If such compensation does not take place, 
accumulation of superoxide radicals and consequent 
cellular damage is to be expected. 
Superoxide radicals are not as reactive toward lipids and 
proteins as are, for example, hydroxyl radicals; super-
oxide can, however, react with nitric oxide (NO) to 
yield peroxinitrite (ONOO-) [15,16], and peroxinitrite 
has been shown to kill neurons in cell culture [15]. In 
addition, peroxinitrite itself can interact with SOD I, at 
low turnover rates, to generate nitronium-like inter-
mediates that are prone to reaction with the tyrosine 
residues of proteins [16,17] (Fig. 1). This alternative 
reaction cascade has been suggested possibly to underlie 
the pathogenesis of familial ALS. But this reaction 
cascade requires the nitration of tyrosine residues with 
peroxinitrite to be catalysed by SOD within the cell and 
so would not be expected to occur in cells deficient in 
SOD. Altered forms of SOD I have, however, been 
characterized, which show reduced scavenging of super-
oxide without the enzyme's reactivity with peroxinitrite 
having been altered, endorsing this suggestion [17]. It 
will be very interesting to learn whether the mutations 
detected in the SOD I gene of familial ALS patients 
cause an increase in the enzyme's ability to catalyze 
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Fig. 2. Three-dimensional structure of the SOD I enzyme. The 
Cu 2+ and Zn 2+ are shown in grey, and the protein domains 
encoded by the exons 1-5 in yellow, green, blue, pink and 
orange, respectively; [3-sheet structures are indicated by arrows. 
The positions of the two point mutations, Ala 4 and Gly 93 are 
indicated by broken arrows. 
tyrosine nitration but decreased catalysis of hydrogen 
peroxide formation. 
Recently, Gurney and co-workers [18] have established 
transgenic mice that over-express two mutated forms of 
human SOD, bearing an Ala 4-+Val mutation and a 
Gly 93-+Ala mutation. The Ala 4-+Val mutation was 
found to be the most frequent mutation in SOD I in 
initial analyses of familial ALS [9]; it is localized within 
the l3-strand region of the enzyme, but it does not affect 
the major loop region that forms the channel around the 
active site Cu2+ and Zn2+ (Fig. 2). This mutation is 
expected to destabilize dimers, which are the normal 
biologically active form of the enzyme (as demonstrated 
by X-ray crystallography) [13]. Indeed, the SOD I 
enzyme activity in red blood cells from patients hetero-
zygous for the Ala 4-+Val mutation is less than 50 % of 
control levels , indicating that the mutation reduces SOD 
activity [9] . In the case of the other mutation analyzed, 
the Gly 93-+ Ala substitution, the mutated residue is 
again not localised within the loop region around the 
active center; instead it lies in the backbone of the 
enzyme (Fig. 2). SOD activity in red blood cells from 
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patients heterozygous for this Gly 93-Ala substitution is 
reduced to about one third of the activity detectable in 
control patients [9]. 
Interestingly, no reduction of SOD I enzyme activity was 
observed in the brains of mice into which these mutant 
human SOD I proteins had been introduced [18] - but 
the mice do still carry two intact mouse SOD I alleles. 
This result indicates that the formation of heterodimers 
between mutant and wild-type SOD I, which in human 
familial ALS patients is thought to be responsible for 
reduced enzyme activity, either might not occur at all in 
the mice or might not lead to reduced SOD I activity. In 
mice over-expressing human SOD I with either 
Ala 4-Val or Gly 93-Ala mutations, significantly 
higher SOD I activities were detected in their brains 
than in those of wild-type mice, corresponding to the 
increased gene copy number and presence of the human 
SOD I protein. As a comparison, mice of the G 12 line, 
which have an average of 2.2 additional copies of human 
SOD I with the Gly 93-Ala mutation, have very similar 
concentrations of human SOD protein and SOD 
enzyme activity in their brains to the levels in mice of 
the N1026 line, which have an average of 3.3 additional 
copies of wild-type human SOD I. This indicates that, in 
contrast to the situation in human patients [9], the muta-
tion does not lead to any reduction of SOD enzyme 
activity in transgenic mice. In addition, mice with a 
transgene carrying the Ala 4-Val mutation also have 
increased SOD enzyme activity, with the level depending 
on transgene copy number. 
Degenerative changes in the motorneurons were 
observed only in mice over-expressing human SOD I 
with the Gly 93-Ala mutation. Mice of this transgenic 
line had the highest levels of SOD I enzyme activity in 
their brain extracts when compared to transgenics over-
expressing either wild-type human SOD I or Ala 4-Val 
mutated SOD I, as a result of the integration of 18 
copies of the transgene (the highest copy number of any 
of the lines). How should these data be interpreted? 
Could it be that degeneration of motorneurons in these 
transgenic mice is not due to the mutation, but results 
simply from increased SOD I enzyme activity? This 
would be consistent with the earlier studies by Avraham 
et al. [4,6], who observed that over-expression of wild-
type SOD I in transgenic mice leads to degenerative 
changes in their motorneurons. 
Why then in the experiments of Gurney and co-workers 
[18] did control mice, over-expressing wild-type SOD I, 
not develop motorneuron degeneration? The answer 
may lie in the amount of transgenically expressed SOD I. 
The mice analyzed by Avraham et al. [4] had up to ten 
times higher SOD I enzyme activity in brain extracts 
than did controls, compared to a maximum of three to 
four times higher levels in the transgenic mice over-
expressing wild-type SOD I that were studied by Gurney 
and co-workers [18], and two-fold higher levels in 
the SOD I transgenic animals reported by Ceballos-Picot 
et al. [5]. In the latter two cases, motorneuron disease did 
not develop. The question of whether animals with the 
genetic background used by Gurney et al. [18] are 
capable of developing motorneuron disease should be 
easily resolved by cross-breeding different founder strains 
of transgenic mice to increase the copy numbers of wild-
type SOD I or the Ala 4-Val mutant form. The results 
of Gurney and co-workers [18] could alternatively be 
explained by the possibility that the Gly 93-Ala muta-
tion changes the activity of SOD I for specific substrates. 
For example, if the mutation increases the affinity specif-
ically for peroxinitrite, then a pathogenic mechanism 
involving peroxinitrite could come into play, as proposed 
by Beckman et al. [16,17]. 
In conclusion, these experiments suggest that not only 
loss of SOD I function, but also excess function or a 
change of substrate specificity, could be responsible for 
motorneuron degeneration in familial ALS patients who 
have mutations in the SOD I gene. It will be very inter-
esting to learn whether over-expression of catalase, or 
other mechanisms leading to the detoxification of hydro-
gen peroxide, can reduce the pathological defects 
observed in transgenic mice over-expressing human 
SOD I. Moreover, the use of drugs such as vitamin E, 
acetylcysteine, L-ascorbate and others, which are known 
to protect cells from hydrogen peroxide and its deriva-
tives [8], could be evaluated in these mice. Although 
some of these compounds have already been tested in 
patients suffering from ALS, no therapeutic effects have 
been demonstrated. It would, however, be of particular 
interest to re-evaluate this approach in patients who are 
known to carry SOD mutations. 
The possibility of treating ALS patients with systemic or 
intrathecally administered recombinant SOD protein, or 
with gene therapeutic strategies aimed at over-expression 
of the human SOD I gene in motorneurons, have to be 
considered with care. It is questionable whether adminis-
tration of SOD could be expected to correct the patho-
genic free radical production in motorneurons. Similarly, 
viral gene therapy would only be a sensible choice if the 
expression of transduced SOD I could be precisely regu-
lated, and if the possibility can be excluded that the 
disease normally develops as a result of the loss of SOD I 
enzyme activity, and not because of a gain in function of 
alternative enzymatic pathways. The experimental results 
described here hold promise for the treatment of human 
motorneuron disease, but translating them into therapies 
will require caution. 
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